Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease

In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC, it failed in patients with Crohn’s disease (CD). This finding strongly hints at a different contribution of JAK...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordes, Friederike, Foell, Dirk, Ding, John Nik, Varga, Georg, Bettenworth, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403801/
https://www.ncbi.nlm.nih.gov/pubmed/32821070
http://dx.doi.org/10.3748/wjg.v26.i28.4055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403801/
https://www.ncbi.nlm.nih.gov/pubmed/32821070
http://dx.doi.org/10.3748/wjg.v26.i28.4055

Ejemplares similares